These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 28064454)

  • 1. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
    Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
    J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY; Kim J; Kim MA; Choi J; Kim WH
    Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
    Wang X; Le P; Liang C; Chan J; Kiewlich D; Miller T; Harris D; Sun L; Rice A; Vasile S; Blake RA; Howlett AR; Patel N; McMahon G; Lipson KE
    Mol Cancer Ther; 2003 Nov; 2(11):1085-92. PubMed ID: 14617781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
    Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
    Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
    Huang X; Gan G; Wang X; Xu T; Xie W
    Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
    Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
    Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).
    Carpenter BL; Chen M; Knifley T; Davis KA; Harrison SMW; Stewart RL; O'Connor KL
    J Biol Chem; 2015 Nov; 290(45):27228-27238. PubMed ID: 26381405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
    Bonine-Summers AR; Aakre ME; Brown KA; Arteaga CL; Pietenpol JA; Moses HL; Cheng N
    Cancer Biol Ther; 2007 Apr; 6(4):561-70. PubMed ID: 17495520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
    Liu D; Zhong M; Zhan D; Zhang Y; Liu S
    Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.